View in EDS HTML Full Text PDF Full Text

Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.

Saved in:
Bibliographic Details
Title: Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.
Authors: Gribben JG; Hematology and Oncology, Barts Cancer Institute, London, UK., Palomba ML; David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Limbrick-Oldfield E; RainCity Analytics, Vancouver, BC, Canada., Palivela M; Kite, A Gilead Company, Santa Monica, CA, USA., Kanters S; RainCity Analytics, Vancouver, BC, Canada., Stilla AM; RainCity Analytics, Vancouver, BC, Canada., Jacobson CA; Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Neelapu SS; Department of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nikolajeva O; Kite, A Gilead Company, Santa Monica, CA, USA., Yan JH; Kite, A Gilead Company, Santa Monica, CA, USA., Ray MD; Kite, A Gilead Company, Santa Monica, CA, USA., Ghione P; David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2026 Apr; Vol. 67 (5), pp. 1184-1188. Date of Electronic Publication: 2025 Dec 30.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1029-2403
DOI:10.1080/10428194.2025.2604306